SCHEMBL3392844

SCHEMBL3392844

CC12CC3CC(CC(C3)C1N)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A2 O15244 2/20 0.41
SLC47A1 Q96FL8 2/20 0.41
MAPT P10636 1/20 0.39
GRIN2D O15399 5/20 0.38
GRIN3B O60391 5/20 0.38
GRIN1 Q05586 5/20 0.38
GRIN2A Q12879 5/20 0.38
GRIN2B Q13224 5/20 0.38
GRIN2C Q14957 5/20 0.38
GRIN3A Q8TCU5 5/20 0.38
LMNA P02545 2/20 0.38
SLC22A1 O15245 1/20 0.38
TSHR P16473 1/20 0.38
NFKB1 P19838 1/20 0.38
STAT6 P42226 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
POLB P06746 1/20 0.36
THRB P10828 1/20 0.36
BLM P54132 1/20 0.36
PMP22 Q01453 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8148766 0.75
SCHEMBL870113 0.72 GRIN2D (0.46) SLC22A2SLC47A1MAPTGRIN2DGRIN3B
SCHEMBL3334426 0.72 SLC22A2 (0.37) SLC22A2SLC47A1MAPTGRIN2DGRIN3B
Phosphine SCHEMBL25171299 0.72 SLC22A2 (0.37) SLC22A2SLC47A1MAPTGRIN2DGRIN3B
SCHEMBL498011 0.72 SLC22A2 (0.37) SLC22A2SLC47A1MAPTGRIN2DGRIN3B
SCHEMBL1697138 0.72 LMNA (0.33) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Hydrochloric Acid SCHEMBL3284553 0.70 LMNA (0.35) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL1015951 0.70 GRIN2D (0.38) SLC22A2SLC47A1GRIN2DGRIN3BGRIN1
SCHEMBL15467179 0.70 GRIN2D (0.38) SLC22A2SLC47A1MAPTGRIN2DGRIN3B
SCHEMBL10415085 0.70 GRIN2D (0.39) SLC22A2SLC47A1MAPTGRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376055-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2024-11-14 US claimed
EP-2817003-A1 COMPOUNDS FOR TREATING PARVOVIRUS INFECTION Aratana Therapeutics NV (BE) 2014-12-31 EP disclosed
WO-2013124403-A1 COMPOUNDS FOR TREATING PARVOVIRUS INFECTION OKAPI SCIENCES NV (BE) 2013-08-29 WO disclosed
EP-1487802-B1 2,3-Diaryl-pyrazolidine derivatives as neurotensin degrading enzyme inhibitors ABBOTT HEALTHCARE PRODUCTS BV (NL) 2010-12-29 EP disclosed
US-7186741-B2 Neurotensin active 2,3,diaryl-pyrazolidine derivatives SOLVAY PHARMACEUTICALS B.V. (NL) 2007-03-06 US disclosed
EP-1684715-A2 COMPOSITIONS COMPRISING CYCLOHEXYLAMINES AND AMINOADAMANTANES Merz Pharma GmbH & Co. KGaA (DE) 2006-08-02 EP disclosed
WO-2005044228-A2 COMPOSITIONS COMPRISING CYCLOHEXYLAMINES AND AMINOADAMANTANES MERZ PHARMA GMBH & CO. KGAA (DE) 2005-05-19 WO disclosed
EP-1487802-A1 NEUROTENSIN ACTIVE 2,3-DIARYL-PYRAZOLIDINE DERIVATIVES Solvay Pharmaceuticals B.V. (NL) 2004-12-22 EP disclosed
US-20040242493-A1 Neurotensin active 2,3,diaryl-pyrazolidine derivatives ABBVIE B.V. (NL) 2004-12-02 US disclosed
WO-2003078400-A1 NEUROTENSIN ACTIVE 2,3-DIARYL-PYRAZOLIDINE DERIVATIVES SOLVAY PHARMACEUTICALS B.V. (NL) 2003-09-25 WO disclosed
EP-0029658-A1 Salts of dihalo-2-quinoxaline carboxylic acids, their preparation and pharmaceutical formulations containing them ELI LILLY AND COMPANY (US) 1981-06-03 EP disclosed
US-4252954-A VIRICIDES ELI LILLY AND COMPANY (US) 1981-02-24 US disclosed
US-4061774-A Halogenated amino methyl adamantane derivatives LILLY INDUSTRIES, LIMITED (EN) 1977-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242493-A1 Neurotensin active 2,3,diaryl-pyrazolidine derivatives NTSR1, NTSR2, NPY1R SLC22A2 2611/4885SLC47A1 641/4885MAPT 2664/4885
US-20240376055-A1 INHIBITORS OF TRANSGLUTAMINASES TGM2, TGM3, TGM1 SLC22A2 1044/4885SLC47A1 997/4885MAPT 989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.